Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.07% | 83.80% | 5.46% | -2.09% | 10.90% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.61% | -208.95% | -114.01% | -63.29% | -75.60% |
| Change in Net Operating Assets | -120.98% | -42.61% | 68.99% | -116.35% | 679.60% |
| Cash from Operations | -19.84% | -26.16% | 25.20% | -43.63% | -19.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.97% | -41.51% | 159.74% | 99.94% | -383.51% |
| Cash from Investing | -45.07% | -41.51% | 165.55% | 99.94% | -383.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 38.49% | -96.25% | 47.68% | -92.37% | 166.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 78.96% | -6,482.05% | -- | 85.31% | 94.33% |
| Cash from Financing | 38.66% | -136.33% | 103.06% | -99.93% | 37.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -183.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.71% | -164.19% | 118.18% | -205.88% | -81.66% |